A phase I/II randomized clinical study of Gettinger et al. and phase II ALTA study Kim et al. showed that brigatinib can produce significant intracranial ORR in patients with ALK-positive NSCLC with intracranial progression or relapse after crizotinib treatment (I/II stage: 53%, ALTA arm A: 46%, ALTA arm B: 67%) and improved intracranial PFS (I/II stage: 14.6 months, ALTA arm A: 15.6 months, ALTA arm B: 18.4 months) [91]. This evidence concerns the gene ALK and non-small cell lung carcinoma.